13F Holdings
中文EN

CBLL Ceribell, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1861107 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.3%
TTM net income YoY-40.8%
TTM EPS YoY-467.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin89.3%
Operating margin-69.8%
Net margin-68.0%
FCF margin-51.9%
EBITDA margin-68.9%

Returns

ROE-52.5%
ROA-41.5%
ROIC (approx.)-55.5%
Asset turnover0.61x

Leverage & solvency

Liabilities / assets24.8%
Debt / equity0.00x
Current ratio8.18x
Interest coverage-47.39x

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$89.06M$65.44M$45.23M
Cost of revenue$10.79M$8.69M$7.06M
Gross profit$78.27M$56.75M$38.16M
R&D expense$19.14M$13.56M$8.99M
SG&A expense$44.45M$33.84M$20.29M
Operating income-$58.40M-$39.71M-$30.04M
Interest expense$1.89M$1.99M$2.10M
Pretax income-$53.41M-$40.45M-$29.45M
Income tax$0$0$11,000
Net income-$53.41M-$40.45M-$29.46M
EBITDA-$57.06M-$38.57M-$29.19M
EPS (basic)-1.46-3.39-5.56
EPS (diluted)-1.46-3.39-5.56
Weighted avg. shares (diluted)36.54M11.95M5.30M
Balance sheet
Cash & equivalents$40.48M$194.37M$34.49M
Short-term investments$118.78M——
Receivables$15.05M$10.88M$7.96M
Inventory$7.29M$6.94M$5.87M
Current assets$186.72M$217.27M$51.96M
PP&E, net$2.03M$2.31M$1.58M
Total assets$195.80M$225.41M$58.92M
Current liabilities$19.19M$12.99M$21.60M
Total liabilities$40.47M$34.25M$23.76M
Shareholders' equity$155.34M$191.16M-$112.25M
Shares outstanding37.49M35.85M5.43M
Cash flow statement
Operating cash flow-$40.81M-$35.04M-$29.16M
Capital expenditure$767,000$1.34M$983,000
Free cash flow-$41.58M-$36.38M-$30.14M
Investing cash flow-$118.14M-$1.60M-$1.76M
Financing cash flow$5.05M$196.52M-$2.82M
Depreciation & amortization$1.34M$1.14M$847,000
Stock-based compensation$12.22M$5.41M$2.68M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.